{"DataElement":{"publicId":"3461832","version":"1","preferredName":"Medullary Thyroid Cancer American Joint Committee on Cancer (AJCC) Edition 7 Group Stage","preferredDefinition":"Stage group determined from information on the tumor (T), regional node (N) and metastases (M) and by grouping cases with similar prognosis for medullary cancer for all age groups.","longName":"3461759v1.0:3461818v1.0","context":"NCI Standards","contextVersion":"1","DataElementConcept":{"publicId":"3461759","version":"1","preferredName":"Thyroid Gland Medullary Carcinoma Stage Grouping","preferredDefinition":"A neuroendocrine carcinoma arising from the C-cells of the thyroid gland.  It is closely associated with multiple endocrine neoplasia syndromes.  Approximately 10% to 20% of medullary thyroid carcinomas are familial.  Patients usually present with a thyroid nodule that is painless and firm.  In the majority of cases nodal involvement is present at diagnosis.  Surgery is the preferred treatment for both primary lesions and recurrences.  This carcinoma is generally not very sensitive to radiation and almost unresponsive to chemotherapy.  - 2002_An assessment based on the combined evaluation of the patient's T stage, M stage, and N stage.","longName":"3461757v1.0:2230143v1.0","context":"NCIP","contextVersion":"1","ObjectClass":{"publicId":"3461757","version":"1","preferredName":"Thyroid Gland Medullary Carcinoma","preferredDefinition":"A neuroendocrine carcinoma arising from the C-cells of the thyroid gland.  It is closely associated with multiple endocrine neoplasia syndromes.  Approximately 10% to 20% of medullary thyroid carcinomas are familial.  Patients usually present with a thyroid nodule that is painless and firm.  In the majority of cases nodal involvement is present at diagnosis.  Surgery is the preferred treatment for both primary lesions and recurrences.  This carcinoma is generally not very sensitive to radiation and almost unresponsive to chemotherapy.  - 2002","longName":"C3879","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Thyroid Gland Medullary Carcinoma","conceptCode":"C3879","definition":"A neuroendocrine carcinoma arising from the C-cells of the thyroid gland. It is closely associated with multiple endocrine neoplasia syndromes. Approximately 10% to 20% of medullary thyroid carcinomas are familial. Patients usually present with a thyroid nodule that is painless and firm. In the majority of cases nodal involvement is present at diagnosis. Surgery is the preferred treatment for both primary lesions and recurrences. This carcinoma is generally not very sensitive to radiation and almost unresponsive to chemotherapy.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"C03DD87C-00C8-38A8-E040-BB89AD4310F6","latestVersionIndicator":"Yes","beginDate":"2012-05-17","endDate":null,"createdBy":"COOPERM","dateCreated":"2012-05-17","modifiedBy":"ONEDATA","dateModified":"2012-05-17","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2230143","version":"1","preferredName":"Stage Grouping","preferredDefinition":"Stage Grouping; an assessment based on the combined evaluation of the patient's T stage, M stage, and N stage. (caDSR)","longName":"C38027","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Stage Grouping","conceptCode":"C38027","definition":"An assessment based on the combined evaluation of the patient's T stage, M stage, and N stage, as well as prognostic parameters for specific cancers.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"F752037A-4CC2-36A8-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-05-18","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2005-05-18","modifiedBy":"ONEDATA","dateModified":"2005-05-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008537","version":"1","preferredName":"Diagnosis","preferredDefinition":"the process of identifying a disease by the signs and symptoms (NCI Glossary).","longName":"DX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B205508C-8324-69B0-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-17","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-17","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C03DD87C-00D6-38A8-E040-BB89AD4310F6","latestVersionIndicator":"Yes","beginDate":"2012-05-17","endDate":null,"createdBy":"COOPERM","dateCreated":"2012-05-17","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":"Created for CRF standard harmonization. mc 5/17/12","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"3461818","version":"1","preferredName":"Thyroid Gland Medullary Carcinoma American Joint Committee on Cancer (AJCC) Edition 7 Group Stage","preferredDefinition":"A neuroendocrine carcinoma arising from the C-cells of the thyroid gland.  It is closely associated with multiple endocrine neoplasia syndromes.  Approximately 10% to 20% of medullary thyroid carcinomas are familial.  Patients usually present with a thyroid nodule that is painless and firm.  In the majority of cases nodal involvement is present at diagnosis.  Surgery is the preferred treatment for both primary lesions and recurrences.  This carcinoma is generally not very sensitive to radiation and almost unresponsive to chemotherapy.  - 2002_A group formed for the purpose of developing a system of clinical staging for cancer that is acceptable to the American medical profession and is compatible with other accepted classifications._An assessment based on the combined evaluation of the patient's T stage, M stage, and N stage._The extent of a cancer within the body, especially whether the disease has spread from the original site to other parts of the body.","longName":"3461818v1.0","context":"NCIP","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":"1","maxLength":"13","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"Stage unknown","valueDescription":"Stage Unknown","ValueMeaning":{"publicId":"3357508","version":"1","preferredName":"Stage Unknown","longName":"3357508","preferredDefinition":"A finding indicating that the extent of organ/tissue involvement by a malignant neoplasm is not reported or not assessed.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Stage Unknown","conceptCode":"C92207","definition":"The extent of organ/tissue involvement by a malignant neoplasm is not reported or not assessed.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B6D76279-6263-2CA8-E040-BB89AD434A54","latestVersionIndicator":"Yes","beginDate":"2012-01-18","endDate":null,"createdBy":"COOPERM","dateCreated":"2012-01-18","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C03E0DED-62A8-9912-E040-BB89AD437BF5","beginDate":"2012-05-17","endDate":null,"createdBy":"COOPERM","dateCreated":"2012-05-17","modifiedBy":"ONEDATA","dateModified":"2012-05-17","deletedIndicator":"No"},{"value":"I","valueDescription":"Stage I Thyroid Gland Medullary Carcinoma","ValueMeaning":{"publicId":"3461819","version":"1","preferredName":"Stage I Thyroid Gland Medullary Carcinoma","longName":"3461819","preferredDefinition":"Stage I includes: T1, N0, M0.  T1: Tumor size 2 cm or less in greatest dimension, limited to the thyroid gland.  N0: No regional lymph node metastasis.  M0: No distant metastasis. (AJCC 7th ed.)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Stage I Thyroid Gland Medullary Carcinoma AJCC v7","conceptCode":"C6133","definition":"Stage I includes: T1, N0, M0.  T1: Tumor size 2 cm or less in greatest dimension, limited to the thyroid gland.  N0: No regional lymph node metastasis.  M0: No distant metastasis. (AJCC 7th ed.)","evsSource":"CTCAE_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C03E0DED-62B4-9912-E040-BB89AD437BF5","latestVersionIndicator":"Yes","beginDate":"2012-05-17","endDate":null,"createdBy":"COOPERM","dateCreated":"2012-05-17","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C03E0DED-62CD-9912-E040-BB89AD437BF5","beginDate":"2012-05-17","endDate":null,"createdBy":"COOPERM","dateCreated":"2012-05-17","modifiedBy":"ONEDATA","dateModified":"2012-05-17","deletedIndicator":"No"},{"value":"II","valueDescription":"Stage II Thyroid Gland Medullary Carcinoma","ValueMeaning":{"publicId":"3461820","version":"1","preferredName":"Stage II Thyroid Gland Medullary Carcinoma","longName":"3461820","preferredDefinition":"Stage II includes: (T2, N0, M0); (T3, N0, M0).  T2: Tumor more than 2 cm but not more than 4 cm in greatest dimension, limited to the thyroid gland.  T3: Tumor more than 4 cm in greatest dimension and limited to the thyroid gland, or tumor of any size with minimal extrathyroid extension (e.g., extension to sternothyroid muscle or perithyroid soft tissues).  N0: No regional lymph node metastasis.  M0: No distant metastasis. (AJCC 7th ed.)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Stage II Thyroid Gland Medullary Carcinoma AJCC v7","conceptCode":"C6134","definition":"Stage II includes: (T2, N0, M0); (T3, N0, M0).  T2: Tumor more than 2 cm but not more than 4 cm in greatest dimension, limited to the thyroid gland.  T3: Tumor more than 4 cm in greatest dimension and limited to the thyroid gland, or tumor of any size with minimal extrathyroid extension (e.g., extension to sternothyroid muscle or perithyroid soft tissues).  N0: No regional lymph node metastasis.  M0: No distant metastasis. (AJCC 7th ed.)","evsSource":"CTCAE_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C03E0DED-62D9-9912-E040-BB89AD437BF5","latestVersionIndicator":"Yes","beginDate":"2012-05-17","endDate":null,"createdBy":"COOPERM","dateCreated":"2012-05-17","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C03E0DED-62F2-9912-E040-BB89AD437BF5","beginDate":"2012-05-17","endDate":null,"createdBy":"COOPERM","dateCreated":"2012-05-17","modifiedBy":"ONEDATA","dateModified":"2012-05-17","deletedIndicator":"No"},{"value":"III","valueDescription":"Stage III Thyroid Gland Medullary Carcinoma","ValueMeaning":{"publicId":"3461821","version":"1","preferredName":"Stage III Thyroid Gland Medullary Carcinoma","longName":"3461821","preferredDefinition":"Stage III includes: (T1, N1a, M0); (T2, N1a, M0); (T3, N1a, M0). T1: Tumor size 2 cm or less in greatest dimension, limited to the thyroid gland.  T2: Tumor more than 2 cm but not more than 4 cm in greatest dimension, limited to the thyroid gland.  T3: Tumor more than 4 cm in greatest dimension and limited to the thyroid gland, or tumor of any size with minimal extrathyroid extension (e.g., extension to sternothyroid muscle or perithyroid soft tissues).  N1a: Metastasis to pretracheal, paratracheal or prelaryngeal/Delphian lymph nodes (Level VI lymph nodes).  M0: No distant metastasis. (AJCC 7th ed.)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Stage III Thyroid Gland Medullary Carcinoma AJCC v7","conceptCode":"C6135","definition":"Stage III includes: (T1, N1a, M0); (T2, N1a, M0); (T3, N1a, M0). T1: Tumor size 2 cm or less in greatest dimension, limited to the thyroid gland.  T2: Tumor more than 2 cm but not more than 4 cm in greatest dimension, limited to the thyroid gland.  T3: Tumor more than 4 cm in greatest dimension and limited to the thyroid gland, or tumor of any size with minimal extrathyroid extension (e.g., extension to sternothyroid muscle or perithyroid soft tissues).  N1a: Metastasis to pretracheal, paratracheal or prelaryngeal/Delphian lymph nodes (Level VI lymph nodes).  M0: No distant metastasis. (AJCC 7th ed.)","evsSource":"CTCAE_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C03E0DED-62FE-9912-E040-BB89AD437BF5","latestVersionIndicator":"Yes","beginDate":"2012-05-17","endDate":null,"createdBy":"COOPERM","dateCreated":"2012-05-17","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C03E0DED-6317-9912-E040-BB89AD437BF5","beginDate":"2012-05-17","endDate":null,"createdBy":"COOPERM","dateCreated":"2012-05-17","modifiedBy":"ONEDATA","dateModified":"2012-05-17","deletedIndicator":"No"},{"value":"IVA","valueDescription":"Stage IVA Thyroid Gland Medullary Carcinoma","ValueMeaning":{"publicId":"3461822","version":"1","preferredName":"Stage IVA Thyroid Gland Medullary Carcinoma","longName":"3461822","preferredDefinition":"Stage IVA includes: (T4a, N0, M0); (T4a, N1a, M0); (T1, N1b, M0); (T2, N1b, M0); (T3, N1b, M0); (T4a, N1b, M0).  T4a: Moderately advanced local disease.  Tumor of any size extending beyond the thyroid gland capsule to invade subcutaneous soft tissues, larynx, trachea, esophagus, or recurrent laryngeal nerve. ).  T1: Tumor size 2 cm or less in greatest dimension, limited to the thyroid gland.  T2: Tumor more than 2 cm but not more than 4 cm in greatest dimension, limited to the thyroid gland.  T3: Tumor more than 4 cm in greatest dimension and limited to the thyroid gland, or tumor of any size with minimal extrathyroid extension (e.g., extension to sternothyroid muscle or perithyroid soft tissues).  T4b: Very advanced disease.  Tumor invades prevertebral fascia or encases carotid artery or mediastinal vessels.  N0: No regional lymph node metastasis.  N1a: Metastasis to pretracheal, paratracheal or prelaryngeal/Delphian lymph nodes (Level VI lymph nodes).  N1b: Metastasis to unilateral, bilateral or contralateral cervical (Levels I, II, III, IV, or V) or retropharyngeal or superior mediastinal lymph nodes (Level VII). M0: No distant metastasis.  (AJCC 7th ed.)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Stage IVA Thyroid Gland Medullary Carcinoma AJCC v7","conceptCode":"C87549","definition":"Stage IVA includes: (T4a, N0, M0); (T4a, N1a, M0); (T1, N1b, M0); (T2, N1b, M0); (T3, N1b, M0); (T4a, N1b, M0).  T4a: Moderately advanced local disease.  Tumor of any size extending beyond the thyroid gland capsule to invade subcutaneous soft tissues, larynx, trachea, esophagus, or recurrent laryngeal nerve.  T1: Tumor size 2 cm or less in greatest dimension, limited to the thyroid gland.  T2: Tumor more than 2 cm but not more than 4 cm in greatest dimension, limited to the thyroid gland.  T3: Tumor more than 4 cm in greatest dimension and limited to the thyroid gland, or tumor of any size with minimal extrathyroid extension (e.g., extension to sternothyroid muscle or perithyroid soft tissues).  T4b: Very advanced disease.  Tumor invades prevertebral fascia or encases carotid artery or mediastinal vessels.  N0: No regional lymph node metastasis.  N1a: Metastasis to pretracheal, paratracheal or prelaryngeal/Delphian lymph nodes (Level VI lymph nodes).  N1b: Metastasis to unilateral, bilateral or contralateral cervical (Levels I, II, III, IV, or V) or retropharyngeal or superior mediastinal lymph nodes (Level VII). M0: No distant metastasis.  (AJCC 7th ed.)","evsSource":"CTCAE_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C03E0DED-6323-9912-E040-BB89AD437BF5","latestVersionIndicator":"Yes","beginDate":"2012-05-17","endDate":null,"createdBy":"COOPERM","dateCreated":"2012-05-17","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C03E0DED-633C-9912-E040-BB89AD437BF5","beginDate":"2012-05-17","endDate":null,"createdBy":"COOPERM","dateCreated":"2012-05-17","modifiedBy":"ONEDATA","dateModified":"2012-05-17","deletedIndicator":"No"},{"value":"IVB","valueDescription":"Stage IVB Thyroid Gland Medullary Carcinoma","ValueMeaning":{"publicId":"3461823","version":"1","preferredName":"Stage IVB Thyroid Gland Medullary Carcinoma","longName":"3461823","preferredDefinition":"Stage IVB includes: T4b, Any N, M0.  T4b: Very advanced disease.  Tumor invades prevertebral fascia or encases carotid artery or mediastinal vessels.  M0: No distant metastasis.  (AJCC 7th ed.)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Stage IVB Thyroid Gland Medullary Carcinoma AJCC v7","conceptCode":"C87550","definition":"Stage IVB includes: T4b, Any N, M0.  T4b: Very advanced disease.  Tumor invades prevertebral fascia or encases carotid artery or mediastinal vessels.  M0: No distant metastasis.  (AJCC 7th ed.)","evsSource":"CTCAE_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C03E0DED-6348-9912-E040-BB89AD437BF5","latestVersionIndicator":"Yes","beginDate":"2012-05-17","endDate":null,"createdBy":"COOPERM","dateCreated":"2012-05-17","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C03E0DED-6361-9912-E040-BB89AD437BF5","beginDate":"2012-05-17","endDate":null,"createdBy":"COOPERM","dateCreated":"2012-05-17","modifiedBy":"ONEDATA","dateModified":"2012-05-17","deletedIndicator":"No"},{"value":"IVC","valueDescription":"Stage IVC Thyroid Gland Medullary Carcinoma","ValueMeaning":{"publicId":"3461824","version":"1","preferredName":"Stage IVC Thyroid Gland Medullary Carcinoma","longName":"3461824","preferredDefinition":"Stage IVC includes: Any T, Any N, M1.  M1: Distant metastasis.  (AJCC 7th ed.)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Stage IVC Thyroid Gland Medullary Carcinoma AJCC v7","conceptCode":"C87551","definition":"Stage IVC includes: Any T, Any N, M1.  M1: Distant metastasis.  (AJCC 7th ed.)","evsSource":"CTCAE_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C03E0DED-636D-9912-E040-BB89AD437BF5","latestVersionIndicator":"Yes","beginDate":"2012-05-17","endDate":null,"createdBy":"COOPERM","dateCreated":"2012-05-17","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C03E0DED-6386-9912-E040-BB89AD437BF5","beginDate":"2012-05-17","endDate":null,"createdBy":"COOPERM","dateCreated":"2012-05-17","modifiedBy":"ONEDATA","dateModified":"2012-05-17","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008537","version":"1","preferredName":"Diagnosis","preferredDefinition":"the process of identifying a disease by the signs and symptoms (NCI Glossary).","longName":"DX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B205508C-8324-69B0-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-17","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-17","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"3461817","version":"1","preferredName":"Thyroid Gland Medullary Carcinoma American Joint Committee on Cancer Stage Grouping Stage","preferredDefinition":"A neuroendocrine carcinoma arising from the C-cells of the thyroid gland.  It is closely associated with multiple endocrine neoplasia syndromes.  Approximately 10% to 20% of medullary thyroid carcinomas are familial.  Patients usually present with a thyroid nodule that is painless and firm.  In the majority of cases nodal involvement is present at diagnosis.  Surgery is the preferred treatment for both primary lesions and recurrences.  This carcinoma is generally not very sensitive to radiation and almost unresponsive to chemotherapy.  - 2002:A group formed for the purpose of developing a system of clinical staging for cancer that is acceptable to the American medical profession and is compatible with other accepted classifications.:An assessment based on the combined evaluation of the patient's T stage, M stage, and N stage.:The extent of a cancer within the body, especially whether the disease has spread from the original site to other parts of the body.","longName":"C3879:C39315:C38027:C16899","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Thyroid Gland Medullary Carcinoma","conceptCode":"C3879","definition":"A neuroendocrine carcinoma arising from the C-cells of the thyroid gland. It is closely associated with multiple endocrine neoplasia syndromes. Approximately 10% to 20% of medullary thyroid carcinomas are familial. Patients usually present with a thyroid nodule that is painless and firm. In the majority of cases nodal involvement is present at diagnosis. Surgery is the preferred treatment for both primary lesions and recurrences. This carcinoma is generally not very sensitive to radiation and almost unresponsive to chemotherapy.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"American Joint Committee on Cancer","conceptCode":"C39315","definition":"A group formed for the purpose of developing a system of clinical staging for cancer that is acceptable to the American medical profession and is compatible with other accepted classifications.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Stage Grouping","conceptCode":"C38027","definition":"An assessment based on the combined evaluation of the patient's T stage, M stage, and N stage, as well as prognostic parameters for specific cancers.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Neoplasm Stage","conceptCode":"C16899","definition":"The extent of a cancer in the body.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C03E0DED-627F-9912-E040-BB89AD437BF5","latestVersionIndicator":"Yes","beginDate":"2012-05-17","endDate":null,"createdBy":"COOPERM","dateCreated":"2012-05-17","modifiedBy":"ONEDATA","dateModified":"2012-05-17","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"AJCC Based:Staging Criteria Based on American Joint Committee on Cancer System","workflowStatus":"RELEASED","registrationStatus":"Application","id":"C03E0DED-6290-9912-E040-BB89AD437BF5","latestVersionIndicator":"Yes","beginDate":"2012-05-17","endDate":null,"createdBy":"COOPERM","dateCreated":"2012-05-17","modifiedBy":"COOPERM","dateModified":"2012-05-17","changeDescription":"Created for CRF standard harmonization. mc 5/17/12","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"2192345","version":"1","longName":"Data Standards","context":"NCIP","ClassificationSchemeItems":[{"publicId":"2859963","version":"1","longName":"Standard CRFs","context":"NCIP"},{"publicId":"3434437","version":"1","longName":"Staging/Extent of Disease (by Disease)","context":"NCIP"},{"publicId":"3434443","version":"1","longName":"Thyroid","context":"NCIP"}]},{"publicId":"3461150","version":"1","longName":"Staging","context":"NCIP","ClassificationSchemeItems":[{"publicId":"3461151","version":"1","longName":"AJCC Edition 7","context":"NCIP"}]},{"publicId":"5574838","version":"1","longName":"Staging/Extent of Disease","context":"NCI Standards","ClassificationSchemeItems":[{"publicId":"10000596","version":"1","longName":"AJCC Edition 7","context":"NCI Standards"},{"publicId":"10000283","version":"1","longName":"Thyroid","context":"NCI Standards"}]}],"AlternateNames":[{"name":"LCC","type":"USED_BY","context":"LCC"},{"name":"AECC","type":"USED_BY","context":"AECC"},{"name":"CITN","type":"USED_BY","context":"CITN"},{"name":"PBTC","type":"USED_BY","context":"PBTC"},{"name":"OHSU Knight","type":"USED_BY","context":"OHSU Knight"}],"ReferenceDocuments":[{"name":"Medullary Disease Stage","type":"Preferred Question Text","description":"Medullary Disease Stage","url":null,"context":"NCI Standards"}],"origin":"AJCC Based:Staging Criteria Based on American Joint Committee on Cancer System","workflowStatus":"RELEASED","registrationStatus":"Preferred Standard","id":"C03E0DED-64CE-9912-E040-BB89AD437BF5","latestVersionIndicator":"Yes","beginDate":"2012-05-17","endDate":null,"createdBy":"COOPERM","dateCreated":"2012-05-17","modifiedBy":"HARTLEYG","dateModified":"2021-06-17","changeDescription":"Created for CRF standard harmonization and released per community approval. mc 5/17/12","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}